CD274 and neoplasm: Given that PD-L1-enriched tumor-derived exosomes suppress T cell activity systemically, thus contributing to immune evasion even in patients undergoing anti-PD-1/PD-L1 therapy, targeting ExoPD-L1, either by inhibiting its biogenesis, release, or function, could restore immune surveillance and enhance the efficacy of existing immunotherapies.